Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2026-05-30 Proxy Solicitation & In…
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Corrigendum to the Newspaper Publication dated 26.05.2026
Proxy Solicitation & Information Statement Classification · 65% confidence The document is a formal filing to BSE/NSE informing shareholders of a corrigendum to the newspaper publication for the Annual General Meeting (AGM) notice and a revised meeting date. This is not the AGM presentation itself (AGM-R) nor the declaration of voting results (DVA), but rather a correction to the pre-meeting notice that was published as part of the proxy solicitation materials. Under our taxonomy, notices, corrigenda, and related information sent to shareholders to solicit votes and inform them of meeting details fall under Proxy Solicitation & Information Statement (PSI).
2026-05-30 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 75% confidence The document includes actual audited standalone and consolidated financial results with detailed numbers for the quarter and year ended March 31, 2020, approved by the Board, along with an independent auditor’s report reference. This constitutes a substantive interim/quarterly report rather than a mere notice or certification. Therefore, it fits the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-30 English
Copy of Newspaper Advertisement intimating 42nd Annual General Meeting scheduled to be held on Friday 26th June,2026 through VC/OAVM.
Regulatory Filings Classification · 75% confidence The text is a SEBI Regulation 30 disclosure submitting copies of newspaper advertisements for the company’s 42nd Annual General Meeting. It is a routine regulatory announcement (Regulatory Filing) rather than an actual financial report, AGM presentation, proxy statement, or earnings release. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-05-26 English
Copy of Newspaper Publication
Regulatory Filings Classification · 85% confidence The document is a BSE/NSE disclosure under SEBI LODR Regulation 30 submitting copies of newspaper advertisements announcing the 42nd Annual General Meeting date. It is not the AGM materials themselves, nor an actual financial report, proxy statement, or voting results. It is a general regulatory announcement, so it falls under the fallback category of Regulatory Filings (RNS).
2026-05-26 English
Transcript of Q4 & FY26 Earnings Conference Call
Call Transcript Classification · 95% confidence The document is a full transcript of Zim Laboratories Limited’s Q4 & FY26 Earnings Conference Call, including prepared remarks and a Q&A session with participants. It is clearly labeled as a transcript of the earnings call. Therefore, it fits the definition of a Call Transcript (CT).
2026-05-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document contains the full transcript of Zim Laboratories Limited’s Q4 & FY26 earnings conference call, including participant lists, moderator instructions, management remarks, and Q&A dialogue. It is not an earnings release summary or presentation but the verbatim transcript of the call, fitting the definition of a Call Transcript.
2026-05-23 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.